ArticleVaccines2026
A Recombinant RABV-G-Based Chemiluminescence Immunoassay for Quantitative Detection of Rabies Virus Antibodies.
Article in Vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundRabies is a nearly 100% fatal zoonosis, and a rabies virus-neutralizing antibody (RVNA) titre of ≥0.5 IU/mL is the recognized correlate of protection, making post-vaccination serological monitoring essential. However, the gold-standard methods (RFFIT and FAVN) are time-consuming, require live virus, and are unsuitable for large-scale surveillance, while current ELISA kits often show poor concordance with neutralization tests.
methodsIn this study, we established a chemiluminescence immunoassay (CLIA) employing magnetic beads coated with recombinant RABV glycoprotein (short-chain) and an acridinium ester-labeled rabbit anti-dog IgG.
resultsThe assay exhibited a detection limit of 0.24 IU/mL. Its performance was validated with 250 canine anti-RABV serum samples against the FAVN. The CLIA and FAVN results were strongly correlated (r = 0.9636,
conclusionsThis CLIA kit eliminates the need for live virus, yields quantitative results within 30 min, and offers simple operation and high-throughput capacity, making it a reliable and practical tool for rabies immune monitoring and scientific prevention and control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.